Drug Search Results
More Filters [+]

XL-228

Alternative Names: xl-228, xl228, xl 228
Latest Update: 2015-08-21
Latest Update Note: Clinical Trial Update

Product Description

XL228 is a small molecule inhibitor of BCR-ABL, SRC and insulin-like growth factor type 1 receptor (IGF1R), which are associated with cancer cell proliferation, survival, and metastasis. The compound also inhibits the T315I mutant form of BCR-ABL, which is resistant to currently approved inhibitors. XL228 is a small molecule protein kinase inhibitor with potent activity against BCR-ABL, including the T315I mutant form which is resistant to currently approved BCR-ABL inhibitors. XL228 also inhibits IGF1R, SRC, FGFR1-3, and the Aurora kinases. (Sourced from: https://ir.exelixis.com/news-releases/news-release-details/exelixis-reports-positive-phase-1-data-xl228-ash-annual-meeting)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Exelixis
Company Location: ALAMEDA CA 94502
Company CEO: Michael M. Morrissey
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for XL-228

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myeloid Leukemia|Lymphoma|Chronic Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Ph+ ALL

P1

Terminated

Acute Lymphoid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia

2010-12-01

XL228-002

P1

Terminated

Lymphoma

2010-12-01

Recent News Events

Date

Type

Title